Showing 461-470 of 1100 results for "".
- BioPharmX Corporation Appoints Craig A. Barbarosh to its Board of Directorshttps://practicaldermatology.com/news/biopharmx-corporation-appoints-craig-a-barbarosh-to-its-board-of-directors/2458734/BioPharmX Corporation appointed Craig A. Barbarosh to its board of directors. He will serve as an independent board member on the audit and compensation committees and will chair the nominating and corporate governance committee. Mr. Barbarosh is a member of the board of directors o
- Class-Action Suit Against EOS Lip Balm Growshttps://practicaldermatology.com/news/class-action-suit-against-eos-lip-balm-grows/2458750/With their colorful egg-shaped containers, palatable price points ($2.99) and assorted fruity and sweet scents, EOS (which stands for Evolution of Smooth) lip balms have been flying off of store shelves for several years. The lip balms have also bec
- Oculus Innovative Sciences Receives FDA Clearance for Microcyn-Based SebDerm Gelhttps://practicaldermatology.com/news/oculus-innovative-sciences-receives-fda-clearance-for-microcyn-based-sebderm-gel/2458780/Oculus Innovative Sciences, Inc. received a new 510(k) clearance from the FDA for the company’s new Microcyn®-based SebDerm Gel. As a prescription product, SebDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrh
- Now Available at Pharmacies: Bayer's Finacea® Foam 15%https://practicaldermatology.com/news/now-available-at-pharmacies-bayers-finacea-azelaic-acid-foam-15/2458835/Bayer HealthCare’s Finacea® (azelaic acid) Foam, 15% in now available at pharmacies nationwide. Finacea Foam was FDA approved in July 2015 for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The approval was based on results
- Novartis Drug Odomzo Gains EU Approval for Locally Advanced Basal Cell Carcinomahttps://practicaldermatology.com/news/novartis-drug-odomzo-gains-eu-approval-for-locally-advanced-basal-cell-carcinoma/2458887/Novartis has announced the European Commission approval of Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to cura
- arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditionshttps://practicaldermatology.com/news/argen-x-and-leo-pharma-enter-into-alliance-to-develop-antibody-based-treatments-for-skin-conditions/2458940/arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, and LEO Pharma entered into an alliance in which they will collaborate to develop antibody-based solutions for the treatment
- ASDS Releases Consensus Recommendations on Basal Cell Carcinomahttps://practicaldermatology.com/news/asds-releases-consensus-recommendations-on-basal-cell-carcinoma/2458947/An expert group of dermatologic surgeons appointed by the American Society for Dermatologic Surgery (ASDS) Board of Directors has developed the first-ever consensus recommendations on the treatment and management of basal cell carcinoma (BCC). According to the ASDS, the document is intend
- Skin Cancer Screening Initiative from AAD: ‘Who's Got Your Back?'https://practicaldermatology.com/news/skin-cancer-screening-initiative-from-aad-whos-got-your-back/2458952/In recognition of Melanoma/Skin Cancer Detection and Prevention Month in May and Melanoma Monday, observed on May 4 this year, the American Academy of Dermatology (AAD) asks the public to consider “Who’s Got Your Back?” when it comes to applying sunscreen and examining skin for
- Three New CeraVe Baby Products Awarded National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/three-new-cerave-baby-products-awarded-national-eczema-association-seal-of-acceptance/2458995/Valeant Pharmaceuticals North America LLC is pleased to announce today that all three products in its newest product line, CeraVe® Baby, have been awarded the National Eczema Association (NEA) Seal of Acceptance™, which maintains rigorous standards for approval. Products include Ce
- The Cetaphil Brand Launches New Cetaphil Baby Linehttps://practicaldermatology.com/news/the-cetaphil-brand-launches-new-cetaphil-baby-line/2459050/Galderma Laboratories, L.P., makers of Cetaphil, launched Cetaphil Baby, a line designed with babies and parents in mind. Cetaphil Baby is formulated with ingredients like organic calendula, almond oil and sunflower oil to soothe sensitive and irritated skin. All Cetaphil Baby products are